| Literature DB >> 26098141 |
Abstract
The current practice for designing single-arm Phase II trials with time-to-event endpoints is limited to using either a maximum likelihood estimate test under the exponential model or a naive approach based on dichotomizing the event time at a landmark time point. A trial designed under the exponential model may not be reliable, and the naive approach is inefficient. The modified one-sample log-rank test statistic proposed in this article fills the void. In general, the proposed test can be used to design single-arm Phase II survival trials under any parametric survival distribution. Simulation results showed that it preserves type I error well and provides adequate power for Phase II cancer trial designs with time-to-event endpoints.Entities:
Keywords: Clinical trial design; one-sample log-rank test; sample size; single-arm Phase II; survival analysis; time-to-event
Mesh:
Year: 2015 PMID: 26098141 PMCID: PMC5223772 DOI: 10.1080/10543406.2015.1052494
Source DB: PubMed Journal: J Biopharm Stat ISSN: 1054-3406 Impact factor: 1.051